Barchart.com
[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Inhibrx Biosciences Inc (INBX)

Inhibrx Biosciences Inc (INBX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Will INBX Continue Burning Cash While Markets Price In Miracles That Haven't Arrived? Barchart - Tue May 12, 4:06PM CDT

Barchart Research What to Expect from INBX Earnings INBX Generated May 12, 2026 Current Price $108.65 EPS Estimate $$-2.37 Consensus Rating Moderate Buy Average Move 4.55% Will INBX Continue Burning Cash...

INBX : 117.95 (+8.56%)
MarketBeat.com
Inhibrx Biosciences’ INBRX-106 Combo Tops KEYTRUDA Alone in Phase 2 Cancer Study MarketBeat - Mon May 11, 11:08AM CDT

Inhibrx Biosciences (NASDAQ:INBX) reported interim randomized Phase 2 data for INBRX-106 in combination with Merck’s KEYTRUDA in first-line PD-L1-positive head and neck squamous cell carcinoma, with...

INBX : 117.95 (+8.56%)
Inhibrx Reports Interim Phase 2 Data for INBRX-106 in First-Line HNSCC; Initial Results Demonstrate Potential Costimulatory Benefit Over PD-1 Monotherapy PR Newswire - Mon May 11, 7:00AM CDT

SAN DIEGO , May 11, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic...

INBX : 117.95 (+8.56%)
Inhibrx To Host Webcast Presentation to Provide Clinical Update on INBRX-106 HexAgon Study in First Line HNSCC PR Newswire - Fri May 8, 3:00PM CDT

– Event to be webcast live on Monday, May 11, 2026, at 5:30 a.m. PT –

INBX : 117.95 (+8.56%)
Inhibrx Provides Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer PR Newswire - Tue Apr 21, 3:05PM CDT

SAN DIEGO , April 21, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing novel biologic therapeutic...

INBX : 117.95 (+8.56%)
Inhibrx To Host Webcast Presentation to Provide Clinical Update on Ozekibart (INBRX-109) in Late Line Colorectal Cancer PR Newswire - Mon Apr 20, 4:03PM CDT

– Event to be webcast live on Tuesday, April 21, 2026, at 1:30 p.m. PT –

INBX : 117.95 (+8.56%)
Inhibrx Reports Fourth Quarter and Fiscal Year 2025 Financial Results PR Newswire - Thu Mar 19, 3:00PM CDT

SAN DIEGO , March 19, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the fourth quarter and fiscal year 2025. Following...

INBX : 117.95 (+8.56%)
Inhibrx Announces Participation in Upcoming Scientific Conference PR Newswire - Mon Mar 2, 3:00PM CST

SAN DIEGO , March 2, 2026 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic...

INBX : 117.95 (+8.56%)
Inhibrx Biosciences Provides Progress Updates on the INBRX-106 Program and the Expansion Cohorts of the ozekibart (INBRX-109) Program PR Newswire - Tue Dec 16, 2025

SAN DIEGO , Dec. 16, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company"), a clinical-stage biopharmaceutical company focused on developing therapeutics for...

INBX : 117.95 (+8.56%)
Inhibrx Reports Third Quarter 2025 Financial Results PR Newswire - Fri Nov 14, 2025

SAN DIEGO , Nov. 14, 2025 /PRNewswire/ -- Inhibrx Biosciences, Inc. (Nasdaq: INBX) ("Inhibrx" or the "Company") today reported financial results for the third quarter of 2025. Following the completion...

INBX : 117.95 (+8.56%)

Barchart Exclusives

Yield Is No Longer King: What These 5 Dividend ETFs Are Telling Investors Barchart - 27 minutes ago
Dividend investing has changed, and yield is misunderstood or misused by many investors. Let's take a closer look at 5 ETFS and discuss what dividend investors should know. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.